This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vogel, C.-A. Articles by Buchegger, F. Search for Related Content PubMed PubMed Citation Articles by Vogel, C.-A. Articles by Buchegger, F.

Radioimmunotherapy and Fractionated Radiotherapy of Human Colon Cancer Liver Metastases in Nude Mice¹

Institute of Biochemistry, University of Lausanne, CH-1066 Epalinges [C-A. V.]; Division of Nuclear Medicine, University Hospital CHUV, CH-1011 Lausanne [C-A. V., M. C. G.]; Institute of Animal Biology, University of Lausanne, CH-1015 Lausanne [M. C. G.]; and Division of Nuclear Medicine, University Hospital HUG, CH-1211 Geneva 14 [F. B.], Switzerland

Radioimmunotherapy (RIT) and radiotherapy (RT) were evaluated in nude mice developing liver metastases of human colon cancer. Without treatment, 90% of preconditioned nude mice, injected with LS174T cells intrasplenically and splenectomized, died between 26 and 93 days after grafting with few to several hundred liver metastases. RIT with 500 µCi of ¹³¹I-labeled anti-carcinoembryonic antigen monoclonal antibodies, injected i.v. in 3 weekly fractions, was initiated 1 to 3 weeks after grafting. Mean survival increase was 43 days for mice treated at 2 weeks. From 13 mice treated at 1 week, 8 mice showed long-term survival, a significantly better cure rate compared to RIT at 2 weeks. Mice undergoing RIT at 3 weeks showed similar survival as untreated controls. Mice injected with ¹³¹I-labeled irrelevant IgG1 or unlabeled antibody showed no significant survival increase. Conventional fractionated external beam RT of the liver showed that 40–50 Gy treatment initiated 1 week after grafting gave long-term survival in 7 of 13 mice, significantly better compared to RT at 2 weeks. With combined RIT + RT initiated 2 weeks after grafting, 5 of 11 mice had long-term survival in the absence of major toxicities. Thus, early RIT and RT were more efficient than later treatments, and combination therapy might give further improvement.

¹ This work was supported by the Cancer League, Section of Solothum, Switzerland (Akt 615) and by the foundation "Swiss Research Against Cancer" (Akt 312).

² To whom requests for reprints should be addressed. Fax: 0041/22/3727169.

Received 8/ 8/96. Accepted 12/ 4/96.

This article has been cited by other articles:

				F. Buchegger, O. W. Press, A. B. Delaloye, and N. Ketterer Radiolabeled and Native Antibodies and the Prospect of Cure of Follicular Lymphoma Oncologist, June 1, 2008; 13(6): 657 - 667. [Abstract] [Full Text] [PDF]

				R. M. Sharkey and D. M. Goldenberg Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies J. Nucl. Med., January 1, 2005; 46(1_suppl): 115S - 127S. [Abstract] [Full Text] [PDF]

				B. Ng, E. Kramer, L. Liebes, C. Wasserheit, H. Hochster, E. Blank, R. Ceriani, and P. Furmanski Radiosensitization of Tumor-targeted Radioimmunotherapy with Prolonged Topotecan Infusion in Human Breast Cancer Xenografts Cancer Res., April 1, 2001; 61(7): 2996 - 3001. [Abstract] [Full Text]

				A. Goel, S. Augustine, J. Baranowska-Kortylewicz, D. Colcher, B. J. M. Booth, G. Pavlinkova, M. Tempero, and S. K. Batra Single-Dose versus Fractionated Radioimmunotherapy of Human Colon Carcinoma Xenografts Using 131I-labeled Multivalent CC49 Single-chain Fvs Clin. Cancer Res., January 1, 2001; 7(1): 175 - 184. [Abstract] [Full Text]

				S. Ruan, J. A. O'Donoghue, S. M. Larson, R. D. Finn, A. Jungbluth, S. Welt, and J. L. Humm Optimizing the Sequence of Combination Therapy with Radiolabeled Antibodies and Fractionated External Beam J. Nucl. Med., November 1, 2000; 41(11): 1905 - 1912. [Abstract] [Full Text] [PDF]

				F. BUCHEGGER, A. ROTH, A. ALLAL, Y. M. DUPERTUIS, D. O. SLOSMAN, A. B. DELALOYE, and J-P. MACH Radioimmunotherapy of Colorectal Cancer Liver Metastases: Combination with Radiotherapy Ann. N.Y. Acad. Sci., June 1, 2000; 910(1): 263 - 270. [Abstract] [Full Text] [PDF]